Alzheimer’s Foundation of America Celebrates 15th Anniversary With 15-State Educational Tour

NEW YORK, Jan. 10, 2017 (GLOBE NEWSWIRE) -- In 1980, Anne Brodsky was diagnosed with Alzheimer’s disease. At the time, there was little information on the illness and nowhere to turn for guidance and support. Years after she passed away, her son, Bert Brodsky, set out to ensure that families living with Alzheimer’s disease did not have to face the illness alone. Brodsky founded the Alzheimer’s Foundation of America’s (AFA) in 2002—15 years ago—as a resource for individuals with Alzheimer’s and related illnesses and their families. Today, AFA has grown to a network of more than 2,600 member organizations nationwide that are dedicated to providing optimal care and services to the more than 5 million Americans living with Alzheimer’s disease and their families. In celebration of its 15th anniversary, AFA is kicking off the “AFA Educating America Tour,” a 15-state tour that aims to help people be proactive about brain health and memory concerns.

Each tour stop will include AFA’s signature “Concepts in Care” Educational Conference for family and professional caregivers, individuals with dementia and the community. Attendees will learn from leading dementia and caregiving experts about topics such as clinical trials and research, access to healthcare, transitioning from home to a residential care setting, safeguarding the home environment, long-term care, and perceptions of aging. The tour will also include community memory screening events, where people can take advantage of free, confidential memory screenings, and a display of the AFA Quilt to Remember.

“AFA is here to offer caregivers education, strategies and support to help them succeed at every step of their caregiving journey,” said Charles J. Fuschillo, Jr., AFA’s president and chief executive officer. “What better way to celebrate our 15th anniversary than to travel the country sharing our resources and bringing awareness of the need for greater caregiver supports, treatments and ultimately, a cure for this devastating illness?”

AFA’s 15th Anniversary Educating America Tour, is made possible by the generous sponsorship of premier presenting sponsor, The Edward N. and Della L. Thome Foundation, Bank of America N.A., Trustee; gold sponsors, Allergan, Eli Lilly and Company and Merck; and teal sponsor CVS Health. The tour will make the following stops:

Location Date
San Francisco, Calif.  February 22
Las Vegas, Nev. March 7
West Palm Beach, Fla. March 27
Phoenix, Ariz. April 5
Tri-State New York/New Jersey area         May 5
Philadelphia, Pa. May 19
Tennessee/Kentucky June 7
Charlotte/Raleigh, N.C. June 20
Virginia/Washington D.C. September 14
Long Island, N.Y. September 26
Chicago, Ill. October 19
Indianapolis, Ind. TBD
Boston, Mass. October 26

Currently, Alzheimer’s disease is the sixth leading cause of death in the United States and the only disease in the top 10 leading causes of death without a cure or meaningful treatment. Until there is a cure, education and advocacy is critical for people who are impacted by the disease.

For more information on AFA’s Educating America Tour, visit or call AFA’s national toll-free helpline at 866-232-8484.

About Alzheimer’s Foundation of America (AFA):

The Alzheimer’s Foundation of America, based in New York, is a non-profit organization that unites more than 2,600 member organizations nationwide in the goal of providing optimal care and services to individuals living with dementia, and to their caregivers and families. Its services include a national, toll-free helpline (866-232-8484) staffed by licensed social workers, educational conferences and materials, a free quarterly magazine for caregivers, the National Memory Screening Program, and “AFA Partners in Care” dementia care training for healthcare professionals. For more information about AFA, call 866-232-8484, visit, follow us on Twitter, or connect with us on Facebook or LinkedIn

Sandy Silverstein
866-232-8484, ext. 104
Tuesday, January 10, 2017 - 13:02

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.